Share
454 Posts.
lightbulb Created with Sketch. 70
clock Created with Sketch.
22/11/21
13:48
Share
Originally posted by wombat777:
↑
Transcript (unedited): [Music] this is amazing discovery what we've discovered is we've known for a long time that the santorini is not damaging to the heart but we haven't known um if it would be protective to the heart what we've discovered is that if you add pysantrine to other drugs that damage the heart we can protect them that damage and this is changes the whole dynamic of how you might use xantrine instead of having to replace the existing drugs which are really well known they're known as anthracyclines you can actually add them keep the anthracycline adding percentage to it and protect the damage from the heart this opens up amazing opportunity clinically commercially and it also the other amazing thing is in combination between those two drugs you get better treatment of the cancer so the cancers are killed at much lower concentrations of the drug much more effectively and the resistance to those drugs is not perfect and so they don't overlap and you end up with a result where the patient's cancer is much better treated they would be by the drug alone amazing discovery really unexpected [Music] well interestingly pillar two was always about breast cancer and we always had shared that we were progressing our credentials in breast cancer because of our cardio toxic or less cardio toxic properties really this is an evolution but a significant evolution because it means that it's beyond us being less cardiotoxic in being cardio protective it means that pillar two has genuine significant clinician interest so if we take it through the clinic successfully clinicians can continue to prescribe anthracyclines as they do but they can use them with more confidence knowing that heart damage is greatly reduced we hope and that would that would really create a very significant outcome for what was or what is pillar ii in breast cancer well two things one that it means that they can actually be treated at the moment many cancer patients get really sub-optimal treatment so the oncologists are so scared of the damage to the heart that they won't treat the patient so they'll give them lower doses or they'll give them fewer doses and the cancer is not treated fully the other thing that allows this is it takes away the major risk of getting a or potentially takes away the major risk that comes with this treatment and that damage to the heart and that's unpredictable sometimes patients even given a low dose of the drug suffer long-term consequences and the doctors don't know before they're treated if that happens or not [Music] well it's of course significant because if you think about anthracyclines as a class they're the most used cancer drug in the world had been for many years continue to be and if you think about what we've discovered and understood potentially in every application of an anthracycline you would equally apply xantrine so that combination means that potentially there are millions and millions of potential treatment opportunities so if you aggregate that in value it's it's an enormous number um you know so we and we'll do our work and we'll figure that out in due course but it's an enormous number so commercially if you think about how you might commercialize we can we can sell zantran independently and it can be used adjunctively with anthracyclines potentially we could co-formulate and have co-formulated products and solutions that might be easier to use in the clinic we can license we can partner there's enormous range of opportunities that will be explored of course down the road no it's um it was always been known that it's been safer drug but it's not been known how or why and i had the hypothesis that maybe it actually wasn't just a safer drug maybe it was actually able to undo the damage that these class drugs do and so we set off with an experiment and to look at this and we discovered that actually it's not only a safer drug it's actually a protective drug and it protects against the damage caused by the anthracyclines amazing outcome couldn't ask for a better result except maybe the discovery that sanctuary targets fto [Music] well our ip position is in bolt embolden because of course we can file ip against its discovery secondly we can formulate and with that formulation we can develop additional ip for that particular use and application so it really does broaden our pattern of state traditionally our patents are being established in a certain area in class but this certainly broadens it significantly so we're really blessed we have a drug that's already in the clinic has a lot of clinical history it's been in 600 more than 1500 patients in more than 60 clinical trials we currently have the drug in the clinical trial right now running in israel we're about to start a trial here here in australia so we have the ability to really quickly translate this discovery from the laboratory into the clinic and actually make a difference to patients and so we're intending to run clinical trial in 2022 so we have this ability to really quickly move this forward this is not a discovery that's maybe five years away maybe 10 years away if everything works out this is something that will happen next year and opens up a massive opportunity for the company and for patients and i think it's really exciting exciting discovery [Music]
Expand
Thank you Wombat... Golden words : "in 2022 so we have this ability to really quickly move this forward this is not a discovery that's maybe five years away maybe 10 years away if everything works out this is something that will happen next year and opens up a massive opportunity for the company and for patients and i think it's really exciting exciting discovery ""